Compare Carvana Co (CVNA) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Cytokinetics Inc — how do they compare? Carvana Co trades at $71.64 (market cap $79.17B), while Cytokinetics Inc trades at $76.3 (market cap $10.63B). The key difference: Carvana Co is far larger — about 7.4× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| CVNA | CYTK | |
|---|---|---|
Market Cap | $79.17B | $10.63B |
Sector | Consumer Cyclical | Technology |
52-Week High | $95.69 | $87.26 |
52-Week Low | $56.27 | $34.31 |
Enterprise Value | $81.65B | $10.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $70.83, down 4.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported record Q2 2026 results with revenue up 52% year-over-year to $7.38 billion and net income of $513 million, though shares fell due to disappointing full-year EBITDA guidance. Strong cash flow generation continues with 2025 operating cash flow of $1.04 billion.
Outlook remains positive with analyst consensus price target of $87.18 implying 23% upside, but execution risks and premium valuation (P/E 38.1) temper enthusiasm. Key risks include profit margin compression and high debt levels despite improving leverage ratios. The stock faces near-term pressure from guidance concerns but maintains long-term growth potential.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
